Company / Operating Margin
ADMA Biologics, Inc. Operating Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
37.5%
FY2025
5-year range
-72.1% / 37.5%
FY2021-FY2025
Trend
+15.2%
vs FY2024
Sector context
#11 of 135
Health Care
What the data says
Among 135 Health Care companies, ADMA Biologics, Inc. is in the top 8% for operating margin. Operating Margin has increased for 3 consecutive years, from -72.1% in FY2022 to 37.5% in FY2025.
Based on SEC 10-K filings.
37.5% in FY2025 with a 5-year CAGR of +191.3%. Top quartile in the Health Care sector.
Improved from 8.4% to 37.5% over the past 2 years.
Health Care sector context is included.
Operating Margin over time
Growth rates
- 3-Year Change
- +109.7pp
- 5-Year Change
- +191.3pp
- 10-Year Change
- -
Sector benchmark
Top 8% in Health CareTop 8% of 135This company 37.5% Sector average -774.4%
▼
+104.8% above sector average
Key checks
Key Insights
- ADMA Biologics, Inc.'s operating margin has grown for 3 consecutive years.
- In FY2025, operating margin increased 15.2% year-over-year.
- Currently 812.0pp above the Health Care sector average.
- Lowest operating margin in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 37.5% | +15.2% |
| FY2024 | 32.6% | +288.9% |
| FY2023 | 8.4% | +111.6% |
| FY2022 | -72.1% | +0.0% |
| FY2021 | -72.1% | +53.1% |
| FY2020 | -153.8% | -8.9% |
| FY2019 | -141.1% | +60.2% |
| FY2018 | -354.9% | -118.4% |
| FY2017 | -162.6% | +0.0% |
| FY2016 | -162.6% | +40.0% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026